Baxalta Inc Set To Abandon Talks With Ariad Pharmaceuticals, Inc.Rupert Hargreaves
According to a report published by Bloomberg this morning, Baxalta Inc. has abandoned its pursuit of Ariad Pharmaceuticals Inc. The report suggests that the deal broke down earlier this week, due to a disagreement over the price Baxalta was willing to pay for its smaller peer.
Shares of Ariad, which develops leukemia and lung cancer treatments, fell as much as 22% in . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email firstname.lastname@example.org and we will get back to you as quick as humanly possible